U.S. FDA flags Aurobindo arm’s Hyderabad plant
The U.S. FDA issued an observation to AuroPeptides, a subsidiary of Aurobindo Pharma, following an inspection of its Hyderabad-area facility. The company stated the issue concerns equipment maintenance and that corrective actions are already underway.
Why it matters
Regulatory scrutiny of pharmaceutical manufacturing plants is critical for maintaining global drug safety and quality standards.
The U.S. Food and Drug Administration (U.S. FDA) has issued one observation to AuroPeptides, the peptide API manufacturing subsidiary of Aurobindo Pharma, following a routine inspection of its facility in Sangareddy district near Hyderabad from August 17 to 21.
The observation relates to facility and equipment maintenance and does not pertain to data integrity or related GMP compliance. Corrective action was already initiated during the course of the inspection and a formal response will be submitted within the stipulated timeline, Aurobindo Pharma said in a filing on Friday.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in